From: Systematic review of influenza resistance to the neuraminidase inhibitors
 |  | Study | Intervention | Patients | |||||
---|---|---|---|---|---|---|---|---|---|
Study first author | Recruitment Period | Design* | Quality score** | Purpose | Dose | Duration | Immunostatus | In/ Out | Age group |
Zanamivir studies | |||||||||
Boivin31 | 1997-1998 | RCT | High | Treatment | 10 mg td | 5 days | Competent | Out | Unclear |
Hedrick36 | 1998-1999 | RCT | High | Treatment | 10 mg td | 5 days | Competent | Out | Children |
Ambrozaitis29 | 1997-2000 | RCT | High | Prophylactic | 10 mg td | 14 days | Competent | In | Adults |
Gravenstein32 | 1997-2000 | RCT | High | Prophylactic | 10 mg td | 14 days | Competent | In | Adults |
Hayden(1)34 | 1999-2000 | RCT | High | Prophylactic | 10 mg td | 10 days | Competent | Out | Adults |
Peramivir study | |||||||||
Barosso(a)30 | 1999-2000 | RCT | High | Treatment | 100, 200, or 400 mg qd, or 200 md q12 h | 5 days | Competent | Out | Adults |
Barosso(b)30 | 1999-2000 | RCT | High | Treatment | 800 mg qd(day1) then400 mg q24 or 400 mg q24 | 5 days | Competent | Out | Adults |
Barosso(c)30 | 1999-2000 | RCT | High | Treatment | 50, 200, or 400 mg qd | 5 days | Competent | Out | Adults |
Barosso(d)30 | 1999-2000 | RCT | High | Treatment | 200, 400 or 800 mg | 5 days | Competent | Out | Adults |
Oseltamivir studies | |||||||||
Whitley38 | 1998-1999 | RCT | High | Treatment | 2 mg/kg twice daily (max 100 mg/day) | 5 days | Competent | Out | Children |
Hayden(2)35 | 2000-2001 | RCT | High | Prophylactic | 75 mg once daily | 10 days | Competent | Out | Mix |
Hayden(3-a)33 | 2000 | RCT | High | Treatment | 75 mg/150 mg once/twice daily | 5 days | Competent | Out | Adult |
Hayden (3-b)33 | 2000 | RCT | High | Treatment | 75 mg once daily | 5 days | Competent | Out | Adult |
Hayden (3-c)33 | 2000 | RCT | High | Prophylactic | 75 mg once daily | 7 days | Competent | Out | Adult |
Ison37 | Before 2009 | RCT | High | Prophylactic | 75 mg orally or suspension once daily for age = > 13, weight-based or suspension for age < 13 | 12 days | Compromised | In | Unclear |
Kiso15 | 2002-2003 | OBS | 6/6 | Treatment | 4 mg/kg | 2-5 days | Competent | Mix | Children |
Kawai42 | 2003-2004 | OBS | 6/6 | Treatment | 75 mg twice daily for adults and children > 35 kg, weight-based twice daily for children < 35 kg | 5 days | Unclear | Out | Mix |
Hatekayama41 | 2004-2005 | OBS | 5/6 | Treatment | Unclear | Unclear | Mix | Unclear | Children |
Stephenson43 | 2005-2007 | OBS | 6/6 | Treatment | Twice daily weight-based dosing regimen | 5 days | Competent | Unclear | Mix |
Cost39 | 2009 | OBS | 4/6 | Prophylactic | Unclear | Unclear | Compromised | In | Children |
Harvala40 | 2009 | OBS | 6/6 | Treatment | Unclear | Unclear | Mix | Unclear | Unclear |
Tramontana44 | 2009 | OBS | 6/6 | Treatment | Varied across patients | Up to 43 days | Compromised | In | Adults |
Wang45 | 2009 | OBS | 6/6 | Treatment | Unclear | Unclear | Mix | In | mix |
Winzer46 | 2009 | OBS | 5/6 | Treatment | Unclear | Unclear | Unclear | Unclear | mix |